Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
01:30pm, Tuesday, 22'nd Jul 2025
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position r
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
10:35am, Tuesday, 22'nd Jul 2025
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investo
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
09:45am, Tuesday, 22'nd Jul 2025
Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United S
NEW YORK , July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Sarepta Therapeutics' stock slips further as company bows to FDA pressure to halt shipments
06:44am, Tuesday, 22'nd Jul 2025
Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.
Sarepta Stock Falls. Why It's Caving Into the FDA and What Comes Next.
05:47am, Tuesday, 22'nd Jul 2025
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.
Sarepta to pause gene therapy Elevidys shipments in US
08:13pm, Monday, 21'st Jul 2025
Sarepta Therapeutics said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental treatme
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
07:40pm, Monday, 21'st Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today, Sarepta Therapeuti
HC Wainwright's Kapoor talks if Sarepta shares could hit $0
06:16pm, Monday, 21'st Jul 2025
Mitchell Kapoor, HC Wainwright, joins 'Fast Money' to talk if Sarepta shares are at risk of hitting $0 and what its path forward is.
Children's Hospital LA pauses use of Sarepta gene therapy for all patients
06:14pm, Monday, 21'st Jul 2025
Children's Hospital Los Angeles, citing recent U.S. Food and Drug Administration actions, on Monday said it has paused usage of Sarepta Therapeutics' gene therapy Elevidys in all patients with muscula
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets
03:06pm, Monday, 21'st Jul 2025
On Friday, the U.S. Food and Drug Administration placed Sarepta Therapeutics Inc.'s SRPT investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold.
